Siemens Healthineers  

• Home
• Products
• Additional Info

Atellica® Hematology Portfolio

The Atellica® Hematology Portfolio* streamlines testing through seamless integration. Scalable high-throughput analyzers offer right-sized solutions. Comprehensive clinical parameters support diverse patient populations. And flexible automation systems† aim to drive efficiency, with intelligent IT that can standardize testing across networks. ... More Info Less Info







The Atellica® Hematology Portfolio* streamlines testing through seamless integration. Scalable analyzers are intended to combine in modular configurations† to maximize throughput or connect with total lab automation† as part of a multidisciplinary, one-touch testing system. They also pair with our Intelligent and open IT solutions to centralize operations and increase transparency and standardization at laboratory and network levels. Most importantly, they deliver the comprehensive results providers need, with enhanced accuracy derived from next-generation flow cytometry and optical methods. Together, it’s a portfolio that can make your laboratory the place where advanced workflow and clinical insight meet to help elevate patient care.

*Not available for sale in the U.S. The products/features mentioned here are not commercially available in all countries. Their future availability cannot be guaranteed.

†Automation connectivity is under development. Not available for sale. Future availability cannot be guaranteed.



SARS-CoV-2 Antibody Assays

The SARS-CoV-2 Total and IgG antibody assays*† provide a semi-quantitative and/or qualitative result. This numerical value will enable detection of the level of antibodies in a patient’s blood sample. Clinicians will have a baseline and be better equipped to assess changes during the course of an individual’s immune response to the SARS-CoV-2 virus.... More Info Less Info







The SARS-CoV-2 Total and IgG antibody assays^*† detect antibodies to the receptor-binding domain (RBD) of the S1 spike antigen, the most unique portion of the SARS-CoV-2 virus. The assays provide a semi-quantitative and/or qualitative result. This numerical value will enable detection of the level of antibodies in a patient’s blood sample. Clinicians will have a baseline and be better equipped to assess changes during the course of an individual’s immune response to the SARS-CoV-2 virus.​

This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for detecting he presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Product availability may vary by country and is subject to varying regulatory requirements.


Atellica® COVID-19 Severity Algorithm*
The Atellica® COVID-19 Severity Algorithm* is an EUO AI-based tool to help identify SARS-CoV-2 patients at risk of severe outcomes. Based on patient demographic and lab data, the algorithm generates a COVID-19 clinical severity score and projected probability of ventilator use, end-stage organ damage, and 30-day in-hospital mortality. *The product is intended for educational use only (EUO). ... More Info Less Info




The Atellica® COVID-19 Severity Algorithm* is an EUO AI-based tool to help identify SARS-CoV-2 patients at risk of progressing to severe outcomes.  By combining age and lab results for D-dimer, Lactate dehydrogenase (LDH), Lymphocyte %, Eosinophil %, Creatinine, C-reactive protein (CRP), Ferritin, PT-INR and Cardiac Troponin-I, the algorithm generates a COVID-19 clinical severity score and likelihood of progression to:  
• Ventilator use,
• End-stage organ damage, and
• 30-day in-hospital mortality
The EUO algorithm is currently being evaluated by laboratories around the world. A potential future interface with Atellica® Data Manager is planned to further expand the middleware’s clinical decision support capabilities.**
*The product is intended for educational use only (EUO). It is not for clinical or patient care, diagnosis, treatment, or to cure or prevent any disease.
**Under development and not available for sale. Future availability cannot be guaranteed


The Enhanced Liver Fibrosis (ELF™) Test

Fatty liver disease is increasing in parallel with the rate of obesity, causing huge health and economic burden. The FDA granted De Novo marketing authorization for the ELF Test for prognostic risk assessment in advanced fibrosis due to NASH. Now there is a simple, reproducible, blood test to help optimize patient management.... More Info Less Info







Fatty liver disease is increasing in alignment with the rate of obesity, resulting in a 178% increase in liver related deaths by 2030.^1,2 There is a clinical need for a simple noninvasive test that is convenient, objective, reproducible, accurate, and widely accessible. The FDA granted De Novo marketing authorization for the ELF Test for prognostic risk assessment in advanced fibrosis due to NASH. The ELF Test simplifies and accelerates the identification of patients with advanced fibrosis (F3 or F4) due to NASH who may benefit most from potentially life-saving preemptive care; an important first-step in turning the tide against the liver’s silent killer.

The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.



epoc® Blood Analysis System with epoc® NXS Host

Patient-side testing is about more than a location. It’s about staying focused on the patient. The system connects the entire team, so it doesn’t matter if the lab staff and caregivers work in different parts of the hospital. Empowered by the epoc® Blood Analysis System, they stand together to advance care delivery.... More Info Less Info







What could happen when critical testing results are securely delivered patient-side in less than 1 minute with a system that connects the entire care team? Patient diagnosis and treatment may happen faster. The hospital may make better use of resources. Patient safety may be enhanced with a simplified testing process and integrated positive patient ID. A streamlined testing workflow could help reduce costs. Outcomes could improve, and a complete, consistent clinical picture would be accessible across the care continuum.  With the epoc® Blood Analysis System as the nexus of care, caregivers and the lab can stay connected to what’s important—being where patients need them most.



N Latex FLC assays: Now cleared for MGUS testing

N Latex FLC kappa and lambda assays from Siemens Healthineers allow specific, reliable, consistent, and sensitive free light chain testing in human serum and plasma. They can be employed for screening, diagnosis, and monitoring of patients with various monoclonal disorders and are the first FDA-cleared free light chain assays for MGUS evaluation.... More Info Less Info







N Latex FLC kappa and lambda assays from Siemens Healthineers allow specific, reliable, consistent, and sensitive free light chain testing in human serum and plasma. They can be employed for screening, diagnosis, and monitoring of patients with various monoclonal disorders and are the first FDA-cleared free light chain assays for MGUS evaluation. Due to the use of monoclonal antibodies, results generated by the assays remain consistent over time. This allows early detection of disease progression and subsequent adjustments to therapy and ultimately contributes to improved patient management and outcomes.



New, Scalable Automation Solutions

As a leader in automation for more than 20 years, we’ve helped optimize workflows with total lab automation over 2200 times. We have a robust IT portfolio and new, more-scalable automation solutions with pre- and post-analytics for labs of all sizes. Let our proven team partner with you to design a workflow that will enable you to achieve your goals.... More Info Less Info







As a leader in automation for more than 20 years, we’ve helped optimize workflows with total lab automation over 2200 times. We have a robust IT portfolio and new, more-scalable automation solutions with pre- and post-analytics for labs of all sizes. Let our proven team partner with you to design a workflow that will enable you to achieve your goals.

• Achieve open, one-touch, end-to-end testing with Aptio® Automation.
• Drive open, one-touch sample preparation in small labs with our planned Atellica® Task Targeted Automation* design.
• Streamline your lab’s chemistry and immunoassay workloads with Atellica® Integrated Automation.

*Distributed by Siemens Healthcare Diagnostics Inc. Product availability varies by country and cannot be guaranteed.



Windows® 10 on Sysmex® CS-5100 Hemostasis System

The Sysmex CS-5100 System from Siemens Healthineers is the only high-volume coagulation analyzer on the market featuring the Windows 10 operating system, considered by Microsoft® to be the most secure version of its operating system released to date.... More Info Less Info







The Sysmex CS-5100 System is the only high-volume coagulation analyzer featuring the Windows 10 operating system, considered by Microsoft to be the most secure version of the Microsoft operating system released to date. It contains a new version of whitelisting McAfee virus protection software, preinstalled on the IPU which brings the system up to the latest cybersecurity standards. Also included are customizable user administration rights and fully traceable results that support comprehensive testing. In addition to cybersecurity protection, the CS systems have preanalytical sample-quality checks using PSITM technology for primary-tube-sample-volume checks and double-aspiration clog detection to provide accurate and reliable results.

Will your company display a new product or promote a new indication/enhanced feature(s) for an existing product in your booth?